Related Experiment Video
Updated: Jul 17, 2026
Assessing Functional Performance in the Mdx Mouse Model
Published on: March 27, 2014
MDMX: from bench to bedside
Jean-Christophe W Marine1, Michael A Dyer, Aart G Jochemsen
1Laboratory For Molecular Cancer Biology, Flanders Interuniversity Institute for Biotechnology (VIB), University of Ghent, B-9052 Ghent, Belgium. chris.marine@dmbr.ugent.be
Abstract:
The tumor suppressor protein p53 is negatively regulated by Mdm2, a ubiquitin ligase protein that targets p53 for degradation. Mdmx (also known as Mdm4) is a relative of Mdm2 that was identified on the basis of its ability to physically interact with p53. An increasing body of evidence, including recent genetic studies, suggests that Mdmx also acts as a key negative regulator of p53. Aberrant expression of MDMX could thus contribute to tumor formation. Indeed, MDMX amplification and/or overexpression occurs in several diverse tumors. Strikingly, recent work identifies MDMX as a specific chemotherapeutic target for treatment of retinoblastoma. Specific MDMX antagonists should therefore be developed as a tool to ensure activation of 'dormant' p53 activity in tumors that retain wild-type p53.
Insights
The tumor suppressor protein Mdmx negatively regulates p53. Inhibiting Mdmx may activate p53 in tumors, offering a new cancer treatment strategy.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- The tumor suppressor protein p53 is crucial for preventing cancer.
- Mdm2 and Mdmx (also known as Mdm4) are key negative regulators of p53.
- Aberrant Mdmx expression is implicated in various tumor formations.
Purpose of the Study:
- To investigate the role of Mdmx as a negative regulator of p53.
- To explore Mdmx as a potential chemotherapeutic target for cancer treatment.
Main Methods:
- Review of genetic studies and existing evidence on Mdmx function.
- Analysis of Mdmx amplification and overexpression in tumors.
Main Results:
- Mdmx physically interacts with p53 and targets it for degradation.
- Mdmx amplification and/or overexpression are observed in diverse tumors.
- Mdmx is identified as a specific therapeutic target for retinoblastoma.
Conclusions:
- Mdmx is a critical negative regulator of p53.
- Targeting Mdmx presents a promising strategy for activating p53 in wild-type p53 tumors.
- Development of Mdmx antagonists is warranted for cancer therapy.
